PE20060417A1 - Indazoles como moduladores de lxrs - Google Patents
Indazoles como moduladores de lxrsInfo
- Publication number
- PE20060417A1 PE20060417A1 PE2005000888A PE2005000888A PE20060417A1 PE 20060417 A1 PE20060417 A1 PE 20060417A1 PE 2005000888 A PE2005000888 A PE 2005000888A PE 2005000888 A PE2005000888 A PE 2005000888A PE 20060417 A1 PE20060417 A1 PE 20060417A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- benzyl
- indazol
- lxrs
- indazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I O Ia, DONDE R1 ES ALQUILO C1-C6, CN, ALQUENILO C2-C6, ALQUINILO C2-C6, FENILO, ENTRE OTROS; R2 ES ALQUILO C3-C8, CICLOALQUILO C3-C8, ALQUINILO C2-C8, ARILO, HETEROARILO, ENTRE OTROS; R3 ES ALQUILO C1-C8, ALQUENILO C2-C8, CICLOALQUILO C3-C8, FENILO, ENTRE OTROS; R4 ES H, HALOGENO, METILO, METOXI; R20 ES H, ALQUILO C1-C3. SON COMPUESTOS PREFERIDOS: 2-BENCIL-3-(4-METOXIFENIL)-7-TRIFLUOROMETIL-2H-INDAZOL; ACIDO 4-[4-(2-BENCIL-7-TRIFLUOROMETIL-2H-INDAZOL-3-IL)-FENOXI]-BENZOICO; ESTER METLICO DEL ACIDO 3-[4-(2-BENCIL-7-TRIFLUOROMETIL-2H-INDAZOL-3-IL)-BENCIL]-BENZOICO; ENTRE OTROS. DICHOS COMPUESTOS SON AGONISTAS DEL LXR (RECEPTOR X DE HIGADO) UTILES EN EL TRATAMIENTO DE ATEROSCLEROSIS, ALZHEIMER, SINDROME CORONARIO AGUDO O RESTENOSIS, ENTRE OTROS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59857304P | 2004-08-03 | 2004-08-03 | |
US66973705P | 2005-04-08 | 2005-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20060417A1 true PE20060417A1 (es) | 2006-06-13 |
Family
ID=35311622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005000888A PE20060417A1 (es) | 2004-08-03 | 2005-08-01 | Indazoles como moduladores de lxrs |
Country Status (21)
Country | Link |
---|---|
US (1) | US7592363B2 (es) |
EP (2) | EP1773781A2 (es) |
JP (1) | JP2008509138A (es) |
KR (1) | KR20070045226A (es) |
CN (1) | CN101213194A (es) |
AR (1) | AR050279A1 (es) |
AU (1) | AU2005271737A1 (es) |
BR (1) | BRPI0514017A (es) |
CA (1) | CA2575180A1 (es) |
CR (1) | CR8888A (es) |
EC (1) | ECSP077223A (es) |
GT (1) | GT200500208A (es) |
IL (1) | IL180759A0 (es) |
MX (1) | MX2007000791A (es) |
NO (1) | NO20070933L (es) |
PA (1) | PA8640701A1 (es) |
PE (1) | PE20060417A1 (es) |
RU (1) | RU2007101488A (es) |
SV (1) | SV2006002187A (es) |
TW (1) | TW200605886A (es) |
WO (1) | WO2006017384A2 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3658525A (en) * | 1970-12-03 | 1972-04-25 | Eastman Kodak Co | Reversal color photographic processes |
TW200409759A (en) * | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
EP1907564B1 (en) | 2005-06-28 | 2013-10-23 | Daiichi Sankyo Company, Limited | Lxr ligand testing method |
US20080070883A1 (en) * | 2006-09-19 | 2008-03-20 | Wyeth | Use of LXR modulators for the prevention and treatment of skin aging |
CA2662965A1 (en) * | 2006-09-19 | 2008-03-27 | Wyeth | Use of lxr agonists for the treatment of osteoarthritis |
ITMI20062230A1 (it) * | 2006-11-22 | 2008-05-23 | Acraf | Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende |
US20100016396A1 (en) * | 2007-01-29 | 2010-01-21 | Hiroshi Imoto | Pyrazole compound |
CA2677264C (en) | 2007-02-02 | 2021-11-30 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
US9233941B2 (en) | 2007-02-02 | 2016-01-12 | Baylor College Of Medicine | Methods and compositions for the treatment of body weight related disorders |
US9085566B2 (en) | 2007-02-02 | 2015-07-21 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and related disorders |
CA2687912C (en) | 2007-06-08 | 2015-11-03 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) * | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
TWI426070B (zh) * | 2007-06-08 | 2014-02-11 | Janssen Pharmaceutica Nv | 六氫吡啶/六氫吡衍生物 |
JP5464709B2 (ja) * | 2007-06-08 | 2014-04-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピペリジン/ピペラジン誘導体 |
US20100331333A1 (en) * | 2007-12-21 | 2010-12-30 | Wyeth Llc | Imidazo [1,2-B] Pyridazine Compounds |
BRPI0822239A2 (pt) * | 2007-12-21 | 2015-06-30 | Wyeth Llc | Composto de pirazolo[1,5-a] pirimidina |
WO2009102789A2 (en) * | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteroarthritis |
PE20140572A1 (es) | 2008-06-05 | 2014-05-16 | Janssen Pharmaceutica Nv | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
WO2011074658A1 (ja) | 2009-12-18 | 2011-06-23 | 田辺三菱製薬株式会社 | 新規抗血小板薬 |
EP2600864B1 (en) * | 2010-08-04 | 2019-01-09 | University Of Virginia Patent Foundation | Compositions and methods for treating inflammatory diseases |
US20130274212A1 (en) | 2010-09-07 | 2013-10-17 | Snu R&Db Foundation | Sesterterpene Compounds and Use Thereof |
EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
EP2697203B1 (en) * | 2011-04-13 | 2017-05-24 | Merck Sharp & Dohme Corporation | Mineralocorticoid receptor antagonists |
JP5959330B2 (ja) * | 2011-06-17 | 2016-08-02 | 田辺三菱製薬株式会社 | 新規抗血小板薬 |
US9567328B2 (en) | 2011-12-21 | 2017-02-14 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
EP3441390A1 (en) | 2012-03-02 | 2019-02-13 | Ralexar Therapeutics, Inc. | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
WO2014026328A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof |
WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
WO2014026330A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
CN104151300B (zh) * | 2013-05-15 | 2018-07-13 | 中国医学科学院医药生物技术研究所 | 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途 |
BR112016004904B1 (pt) | 2013-09-04 | 2023-01-24 | Ellora Therapeutics, Inc. | Compostos moduladores de receptor x do fígado (lxr), seu uso e composição farmaceutica compreendendo os mesmos |
EP3041834A4 (en) | 2013-09-04 | 2017-01-18 | Ralexar Therapeutics, Inc. | Liver x receptor (lxr) modulators |
WO2015089218A1 (en) * | 2013-12-10 | 2015-06-18 | David Wustrow | Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex |
AU2015204572B2 (en) | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
EA031317B1 (ru) * | 2014-01-20 | 2018-12-28 | Клив Байосайенсиз, Инк. | КОНДЕНСИРОВАННЫЕ ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КОМПЛЕКСА p97 |
WO2016057454A1 (en) | 2014-10-06 | 2016-04-14 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
US10221142B2 (en) | 2015-02-11 | 2019-03-05 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof |
CN109234294B (zh) * | 2015-07-03 | 2022-09-23 | 赣南师范大学 | 一种微生物体内基于脂酰-acp合成脂肪醇乙酸酯的方法 |
CN105153125A (zh) * | 2015-09-29 | 2015-12-16 | 青岛友诚高新技术有限公司 | 一种可用于制备保护心肌缺血药物的化合物及其制备方法、用途 |
JP2018531958A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害薬としてのヘテロアリール置換安息香酸及びその使用 |
US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
US10287272B2 (en) | 2015-10-27 | 2019-05-14 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
AU2017207291B2 (en) | 2016-01-11 | 2023-06-15 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
ES2791317T3 (es) * | 2016-02-24 | 2020-11-03 | Acesion Pharma Aps | Nuevos inhibidores de los canales de potasio |
CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
TWI748194B (zh) * | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
MA54296A (fr) | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc | Procédés de traitement du métabolisme lipidique dérégulé |
MX2021014679A (es) * | 2019-05-31 | 2022-04-06 | Janssen Pharmaceutica Nv | Inhibidores de molécula pequeña de quinasa inductora de nf-kb. |
US20220257596A1 (en) | 2019-07-15 | 2022-08-18 | Novartis Ag | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
US20220281824A1 (en) * | 2019-07-30 | 2022-09-08 | Oregon State University | Aryl hydrocarbon receptor activators |
JP2023509845A (ja) | 2019-12-13 | 2023-03-10 | インスピルナ,インコーポレーテッド | 金属塩及びその使用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152135A (en) * | 1962-11-02 | 1964-10-06 | Warner Lambert Pharmaceutical | Heterocyclic substituted indazole compounds and process therefor |
US3541110A (en) * | 1967-01-20 | 1970-11-17 | American Home Prod | Indazole-5-sulfonamides |
IL84944A (en) | 1987-01-19 | 1992-02-16 | Ici Plc | Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation |
US5321028A (en) * | 1988-09-02 | 1994-06-14 | Janssen Pharmaceutica N.V. | Antihypertensive 3-piperidinyl-indazole derivatives |
FR2673628B1 (fr) | 1991-03-07 | 1993-07-09 | Esteve Labor Dr | Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles. |
JPH04282372A (ja) | 1991-03-08 | 1992-10-07 | Nissan Chem Ind Ltd | インダゾール誘導体の製造方法 |
US6005109A (en) * | 1997-10-30 | 1999-12-21 | Pflizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
JPH0717950A (ja) | 1993-06-29 | 1995-01-20 | Fuji Photo Film Co Ltd | アゾ化合物の製造方法と得られたアゾ化合物を用いたインダゾールの製造方法 |
DE19612291A1 (de) | 1996-03-28 | 1997-10-02 | Bernhard K Prof Dr Dr Keppler | Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe |
DE19744026A1 (de) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
BR9815211B1 (pt) * | 1997-10-24 | 2011-06-28 | compostos sulfamoila e fungicidas agrìcolas ou hortìcolas. | |
GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
CA2370265A1 (en) | 1999-04-20 | 2000-10-26 | Syngenta Limited | Pesticidal indazole or benzotriazole derivatives |
HUP0203954A2 (hu) | 1999-09-17 | 2003-03-28 | Millennium Pharmaceuticals, Inc. | Xa faktor inhibitorok |
US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
EP1254115A2 (en) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
DE60115394T2 (de) | 2000-02-29 | 2006-10-19 | Millennium Pharmaceuticals, Inc., Cambridge | Benzamide und ähnliche inhibitoren vom faktor xa |
AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
AU2001277621A1 (en) | 2000-08-09 | 2002-03-04 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
DE10046029A1 (de) * | 2000-09-18 | 2002-03-28 | Bayer Ag | Indazole |
JP2004536113A (ja) * | 2001-07-03 | 2004-12-02 | カイロン コーポレイション | チロシンキナーゼおよびセリン/スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物 |
US7101884B2 (en) * | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US20030109550A1 (en) | 2001-09-19 | 2003-06-12 | Michael Clare | Substituted indazole compounds for the treatment of inflammation |
AU2002334217B2 (en) * | 2001-10-26 | 2008-07-03 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
TW200409759A (en) * | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
AU2003286180B2 (en) | 2002-12-02 | 2009-11-12 | F. Hoffmann-La Roche Ag | Indazole derivatives as CRF antagonists |
CA2535406A1 (en) * | 2003-08-14 | 2005-02-24 | F. Hoffmann-La Roche Ag | Gabanergic modulators |
US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
-
2005
- 2005-08-01 PA PA20058640701A patent/PA8640701A1/es unknown
- 2005-08-01 GT GT200500208A patent/GT200500208A/es unknown
- 2005-08-01 AU AU2005271737A patent/AU2005271737A1/en not_active Abandoned
- 2005-08-01 MX MX2007000791A patent/MX2007000791A/es active IP Right Grant
- 2005-08-01 KR KR1020077002741A patent/KR20070045226A/ko not_active Application Discontinuation
- 2005-08-01 EP EP05777241A patent/EP1773781A2/en not_active Withdrawn
- 2005-08-01 EP EP10177298A patent/EP2295429A1/en not_active Withdrawn
- 2005-08-01 US US11/194,263 patent/US7592363B2/en not_active Expired - Fee Related
- 2005-08-01 JP JP2007524862A patent/JP2008509138A/ja active Pending
- 2005-08-01 BR BRPI0514017-0A patent/BRPI0514017A/pt not_active IP Right Cessation
- 2005-08-01 PE PE2005000888A patent/PE20060417A1/es not_active Application Discontinuation
- 2005-08-01 AR ARP050103205A patent/AR050279A1/es not_active Application Discontinuation
- 2005-08-01 CA CA002575180A patent/CA2575180A1/en not_active Abandoned
- 2005-08-01 TW TW094125997A patent/TW200605886A/zh unknown
- 2005-08-01 CN CNA2005800309245A patent/CN101213194A/zh active Pending
- 2005-08-01 WO PCT/US2005/026970 patent/WO2006017384A2/en active Application Filing
- 2005-08-01 RU RU2007101488/04A patent/RU2007101488A/ru not_active Application Discontinuation
- 2005-08-08 SV SV2005002187A patent/SV2006002187A/es not_active Application Discontinuation
-
2007
- 2007-01-17 IL IL180759A patent/IL180759A0/en unknown
- 2007-02-01 CR CR8888A patent/CR8888A/es not_active Application Discontinuation
- 2007-02-02 EC EC2007007223A patent/ECSP077223A/es unknown
- 2007-02-19 NO NO20070933A patent/NO20070933L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2575180A1 (en) | 2006-02-16 |
RU2007101488A (ru) | 2008-09-10 |
US7592363B2 (en) | 2009-09-22 |
AR050279A1 (es) | 2006-10-11 |
AU2005271737A1 (en) | 2006-02-16 |
IL180759A0 (en) | 2007-06-03 |
CN101213194A (zh) | 2008-07-02 |
TW200605886A (en) | 2006-02-16 |
JP2008509138A (ja) | 2008-03-27 |
BRPI0514017A (pt) | 2008-05-27 |
NO20070933L (no) | 2007-03-28 |
EP1773781A2 (en) | 2007-04-18 |
PA8640701A1 (es) | 2006-09-08 |
KR20070045226A (ko) | 2007-05-02 |
GT200500208A (es) | 2006-03-02 |
EP2295429A1 (en) | 2011-03-16 |
WO2006017384A3 (en) | 2007-09-20 |
ECSP077223A (es) | 2007-03-29 |
WO2006017384A2 (en) | 2006-02-16 |
SV2006002187A (es) | 2006-09-14 |
US20060030612A1 (en) | 2006-02-09 |
CR8888A (es) | 2007-08-28 |
MX2007000791A (es) | 2007-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20060417A1 (es) | Indazoles como moduladores de lxrs | |
PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
PE20090992A1 (es) | Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa | |
PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico | |
PE20110906A1 (es) | Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif | |
ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
PE20081199A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa | |
PE20090326A1 (es) | Compuestos heterociclos como inhibidores de erk | |
PE20100138A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k | |
PE20070141A1 (es) | Derivados de isoquinolina como inhibidores de rho-cinasa | |
CO6220851A2 (es) | Compuestos de ciclohexandiona sustituidos en la posicion 5 | |
PE20120399A1 (es) | Derivados del l-(piperidin-4-il)-pirazol como moduladores de gpr 119 | |
PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
CO6140060A2 (es) | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 | |
PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
PE20040516A1 (es) | Derivados de 1,2-azol | |
AR049784A1 (es) | Derivados sustituidos de morfolina y tiomorfolina | |
PE20080068A1 (es) | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora | |
PE20090290A1 (es) | Derivados de pirrolopiridina como inhibidores de bace | |
EA200800182A1 (ru) | Циклические анилинопиридинотриазины в качестве ингибиторов gsk-3 | |
PE20050676A1 (es) | Quinolinas referidas a enfermedades cardiovasculares | |
AR054130A1 (es) | Procedimiento para la preparacion de 1-alquil-3-feniluracilos | |
AR073932A1 (es) | Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion | |
AR046625A1 (es) | Derivados de pirazol y composiciones farmaceuticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |